Purchase Order 75D30122P13777
Award Date
8/31/22
Potential Completion Date
9/30/22
Potential Value
$129K
Federal Agency
CDC Pittsburgh
Awardee
Qiagen, LLC
Ultimate Awardee
Qiagen N.V.
NAICS Category
325413 - In-Vitro Diagnostic Substance Manufacturing
PSC Category
6640 - Laboratory Equipment And Supplies
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Germantown, MD, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price purchase order contract awarded by the Centers for Disease Control and Prevention (CDC) to Qiagen, LLC, a division of Qiagen N.V., for the provision of laboratory supplies. The contract has a ceiling value of $75,149.98 and a completion date of August 30, 2018. Qiagen is an international provider of sample and assay technologies for molecular diagnostics, applied testing, pharma, and academic applications, and has previously supplied goods and services to various...
This is a $14,288 firm fixed-price purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Qiagen, LLC, a division of Qiagen N.V. The contract has a period of performance from April 1, 2025 to March 31, 2026 for Qiagen to provide laboratory services under the IP0023 Statement of Work. No set-aside designation was used. Qiagen is an international provider of sample and assay technologies for molecular diagnostics, applied testing, and other applications. The company...
This is a $145,237 firm fixed-price purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Qiagen, LLC, a subsidiary of the multinational biotechnology company Qiagen N.V. The contract is for "other functions" and does not have a set-aside designation. Qiagen is a provider of sample and assay technologies for molecular diagnostics, applied testing, pharma, and academic research. Under this award, Qiagen is likely providing products and services to support the...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $55,000.00 firm fixed price purchase order contract to Qiagen, LLC, a division of Qiagen N.V., an international provider of sample and assay technologies for molecular diagnostics, applied testing, pharma, and academics. This contract has a completion date of May 21, 2024. Qiagen is a foreign-owned, for-profit manufacturer that has provided a range of products and services to support federal...
This firm-fixed-price purchase order was awarded by the Centers for Disease Control and Prevention (CDC) to Qiagen, LLC, a subsidiary of the multinational biotechnology company Qiagen N.V. The $64,817.75 contract provides planned maintenance services for QIAGEN equipment, with a period of performance through March 31, 2024. Qiagen is a major supplier of molecular diagnostics products and services to federal agencies, including the Department of Health and Human Services, Department of Veterans...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a firm-fixed price purchase order contract to Qiagen, LLC, a division of the international provider of sample and assay technologies Qiagen N.V. The $38,760.96 contract is for laboratory supplies to be delivered by November 1, 2022. Qiagen has provided a range of products and services to support federal agencies' biomedical research, public health, law enforcement, and healthcare programs under past...
This is a $211,853.58 firm fixed-price purchase order awarded by the Defense Health Agency to Qiagen, LLC, a foreign-owned, for-profit manufacturer of molecular diagnostics, laboratory equipment, and bioinformatics software. The contract is for QCII ONE PRECUR 301-600 TESTING, with a period of performance through May 31, 2027. Qiagen, LLC is a subsidiary of the multinational biotechnology company Qiagen N.V., which has a significant federal contract portfolio supporting biomedical research,...
The U.S. Centers for Disease Control and Prevention (CDC) awarded a $60,250.00 firm fixed price purchase order contract to Qiagen, LLC, a division of the parent company Qiagen N.V. The contract has an ultimate completion date of September 28, 2024 and was awarded on September 29, 2023. Qiagen is an international provider of sample and assay technologies for molecular diagnostics, applied testing, pharmaceuticals, and academics. This contract does not have a set-aside designation. Qiagen has...
This firm fixed-price purchase order was awarded by the Centers for Disease Control and Prevention (CDC) to Qiagen, LLC, a division of the international provider of sample and assay technologies Qiagen N.V. The $148,000.00 contract is for the delivery of products and services to support the CDC's biomedical research, public health, and healthcare programs. This includes DNA/RNA extraction kits, next-generation sequencing, digital PCR systems, sample preparation equipment, bioinformatics...
This is a firm fixed-price purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Qiagen, LLC, a subsidiary of the Qiagen N.V. biotechnology company. The $113,138.05 contract is for the provision of QIACUBE HT/QIAXTRACTOR platform equipment, which supports the CDC's biomedical research, public health, and healthcare programs. Qiagen is a well-established federal contractor, holding multiple indefinite delivery vehicles (IDVs) and blanket purchase agreements (BPAs) with...